Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with hereditary amyloidosis and polyneuropathy, according to the results of a ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Researchers have identified molecular mechanisms behind age-related memory decline — and shown they can be reversed.

Crispr Therapeutics AG has experienced a notable decline in its stock price over the past week, dropping by 8.60%. This downturn comes despite several positive analyst ratings and price target ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.